Mice that expressed a catalytically inactive mutant CerS2 developed hepatocellular carcinoma (HCC) at a young age (8 weeks), while mice that were deficient for CerS2 developed liver adenoma and HCC later in adulthood (7–10 months) [76,77,78]. This evidence concerns the gene CERS2 and hepatocellular carcinoma.